487 NC410, a fusion protein of LAIR-2 (Leukocyte Associated Immunoglobulin-like Receptor) with human IgG1 Fc, is safe & tolerable with evidence of immune modulation in subjects with advanced solid tumors Article Swipe

PDF

Han Myint , Linjie Tian , Jahangheer Shaik , Emilia Barbu , Qinjie Zhou , Aaron Morawski , Hasan Abukharma , Linda Liu , John Y. Shin , Dallas B. Flies , Ron Copeland , Megan Nelson , Stephanie Zeidan , Marijo Bilušić , Danielle M. Pastor , Ravi A. Madan , Siqing Fu , Martin Gutierrez , Solomon Langermann ·

YOU? · · 2021 · Open Access · · DOI: https://doi.org/10.1136/jitc-2021-sitc2021.487

Background Collagen and C1q in the extracellular matrix (ECM), are the predominant ligands for LAIR-1, an inhibitory receptor expressed on the cell surface of several immune cell subsets that inhibits immune activation and migration. LAIR-2, a soluble homolog of LAIR-1, competes for binding to collagen and C1q and serves as a natural decoy to promote immune function under normal conditions. Dysregulation of the ECM and increased expression of collagen and C1q within the tumor microenvironment (TME) plays a critical role in promoting tumor progression. NC410 was engineered to overcome this highly immunosuppressive environment by blocking LAIR-1 function, reversing immune suppression, and inducing ECM remodeling to promote immune cell infiltration within the TME. Methods This is a first in human, phase 1/2, open-label, single-armed dose-escalation study to determine the safety, tolerability, dose-limiting toxicity (DLT), maximum tolerated dose (MTD), recommended phase 2 dose, preliminary efficacy and to explore pharmacodynamic biomarkers of NC410 (figure 1). Key eligibility criteria include subjects with advanced or metastatic solid tumors with measurable disease based on RECIST v1.1. Results As of 07/22/2021, a total of 16 patients have been enrolled, treated, and completed the DLT period. NC410 (up to 60 mg), was well tolerated, with no safety concerns, infusion-related toxicities, or DLT reported. No anti-drug antibody (ADA) was detected post-NC410 up to 60 mg treatment. As expected, the C1Q level decreased immediately after the NC410 infusion and was replenished after two hours. Evaluation from samples to date available up to cycle 5 suggests that there was no reduction in the baseline C1Q level with subsequent dosing (figure 2). LAIR-2 levels continued to increase in a dose-dependent fashion post-NC410 dosing and marginal increase pre-dose (figure 3). Interestingly, we observed an increase in soluble LAIR-1 over time in a similar pattern to LAIR-2 (figure 4). Furthermore, immunophenotyping of patient whole blood suggests a trend towards an increase in CD4+ and CD8+ T cells including LAIR-1+ T cells in cohort 4, although overall expression levels of LAIR-1 did not appear to increase (ongoing analysis). Cytokines, chemokines, and collagen degradation products (CDP) will be evaluated as potential pharmacodynamic biomarkers as we continue through higher dose cohorts. Conclusions Preliminary evaluation of NC410 in subjects with advanced or metastatic solid tumors appears to be safe and well-tolerated with evidence of immune modulation consistent with predictive PK/PD modeling in a Phase 1/2 open-label study. Further evaluation will be done with increasing doses to confirm these initial findings. Trial Registration NCT04408599 Ethics Approval This study has been approved by the IRB of all the participating institutions, and all participants have given informed consent before taking part in the study. Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Related Topics

Concepts

Immune system Tolerability Pharmacodynamics Medicine Antibody Extracellular matrix Cancer research Tumor microenvironment Pharmacokinetics Pharmacology Immunology Internal medicine Adverse effect Biology Cell biology

Metadata

Type: article
Language: en
Landing Page: https://doi.org/10.1136/jitc-2021-sitc2021.487
PDF: https://jitc.bmj.com/content/jitc/9/Suppl_2/A516.full.pdf
OA Status: bronze
Cited By: 1
Related Works: 10
OpenAlex ID: https://openalex.org/W3213366366

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W3213366366

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1136/jitc-2021-sitc2021.487

Digital Object Identifier
Title: 487 NC410, a fusion protein of LAIR-2 (Leukocyte Associated Immunoglobulin-like Receptor) with human IgG1 Fc, is safe & tolerable with evidence of immune modulation in subjects with advanced solid tumors

Work title
Type: article

OpenAlex work type
Language: en

Primary language
Publication year: 2021

Year of publication
Publication date: 2021-11-01

Full publication date if available
Authors: Han Myint, Linjie Tian, Jahangheer Shaik, Emilia Barbu, Qinjie Zhou, Aaron Morawski, Hasan Abukharma, Linda Liu, John Y. Shin, Dallas B. Flies, Ron Copeland, Megan Nelson, Stephanie Zeidan, Marijo Bilušić, Danielle M. Pastor, Ravi A. Madan, Siqing Fu, Martin Gutierrez, Solomon Langermann

List of authors in order
Landing page: https://doi.org/10.1136/jitc-2021-sitc2021.487

Publisher landing page
PDF URL: https://jitc.bmj.com/content/jitc/9/Suppl_2/A516.full.pdf

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: bronze

Open access status per OpenAlex
OA URL: https://jitc.bmj.com/content/jitc/9/Suppl_2/A516.full.pdf

Direct OA link when available
Concepts: Immune system, Tolerability, Pharmacodynamics, Medicine, Antibody, Extracellular matrix, Cancer research, Tumor microenvironment, Pharmacokinetics, Pharmacology, Immunology, Internal medicine, Adverse effect, Biology, Cell biology

Top concepts (fields/topics) attached by OpenAlex
Cited by: 1

Total citation count in OpenAlex
Citations by year (recent): 2022: 1

Per-year citation counts (last 5 years)
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W3213366366
doi	https://doi.org/10.1136/jitc-2021-sitc2021.487
ids.doi	https://doi.org/10.1136/jitc-2021-sitc2021.487
ids.mag	3213366366
ids.openalex	https://openalex.org/W3213366366
fwci	0.10483149
type	article
title	487 NC410, a fusion protein of LAIR-2 (Leukocyte Associated Immunoglobulin-like Receptor) with human IgG1 Fc, is safe & tolerable with evidence of immune modulation in subjects with advanced solid tumors
biblio.issue
biblio.volume
biblio.last_page	A517
biblio.first_page	A516
topics[0].id	https://openalex.org/T10158
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.9930999875068665
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2730
topics[0].subfield.display_name	Oncology
topics[0].display_name	Cancer Immunotherapy and Biomarkers
topics[1].id	https://openalex.org/T11016
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.9757999777793884
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2741
topics[1].subfield.display_name	Radiology, Nuclear Medicine and Imaging
topics[1].display_name	Monoclonal and Polyclonal Antibodies Research
topics[2].id	https://openalex.org/T10580
topics[2].field.id	https://openalex.org/fields/24
topics[2].field.display_name	Immunology and Microbiology
topics[2].score	0.9684000015258789
topics[2].domain.id	https://openalex.org/domains/1
topics[2].domain.display_name	Life Sciences
topics[2].subfield.id	https://openalex.org/subfields/2403
topics[2].subfield.display_name	Immunology
topics[2].display_name	Immunotherapy and Immune Responses
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C8891405
concepts[0].level	2
concepts[0].score	0.6995174884796143
concepts[0].wikidata	https://www.wikidata.org/wiki/Q1059
concepts[0].display_name	Immune system
concepts[1].id	https://openalex.org/C2778375690
concepts[1].level	3
concepts[1].score	0.6951682567596436
concepts[1].wikidata	https://www.wikidata.org/wiki/Q7814214
concepts[1].display_name	Tolerability
concepts[2].id	https://openalex.org/C111113717
concepts[2].level	3
concepts[2].score	0.5622907876968384
concepts[2].wikidata	https://www.wikidata.org/wiki/Q725307
concepts[2].display_name	Pharmacodynamics
concepts[3].id	https://openalex.org/C71924100
concepts[3].level	0
concepts[3].score	0.5278306603431702
concepts[3].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[3].display_name	Medicine
concepts[4].id	https://openalex.org/C159654299
concepts[4].level	2
concepts[4].score	0.5156580209732056
concepts[4].wikidata	https://www.wikidata.org/wiki/Q79460
concepts[4].display_name	Antibody
concepts[5].id	https://openalex.org/C189165786
concepts[5].level	2
concepts[5].score	0.5141211152076721
concepts[5].wikidata	https://www.wikidata.org/wiki/Q193825
concepts[5].display_name	Extracellular matrix
concepts[6].id	https://openalex.org/C502942594
concepts[6].level	1
concepts[6].score	0.4947476089000702
concepts[6].wikidata	https://www.wikidata.org/wiki/Q3421914
concepts[6].display_name	Cancer research
concepts[7].id	https://openalex.org/C2776107976
concepts[7].level	3
concepts[7].score	0.4843903183937073
concepts[7].wikidata	https://www.wikidata.org/wiki/Q1786433
concepts[7].display_name	Tumor microenvironment
concepts[8].id	https://openalex.org/C112705442
concepts[8].level	2
concepts[8].score	0.4109783470630646
concepts[8].wikidata	https://www.wikidata.org/wiki/Q323936
concepts[8].display_name	Pharmacokinetics
concepts[9].id	https://openalex.org/C98274493
concepts[9].level	1
concepts[9].score	0.37706029415130615
concepts[9].wikidata	https://www.wikidata.org/wiki/Q128406
concepts[9].display_name	Pharmacology
concepts[10].id	https://openalex.org/C203014093
concepts[10].level	1
concepts[10].score	0.3280024528503418
concepts[10].wikidata	https://www.wikidata.org/wiki/Q101929
concepts[10].display_name	Immunology
concepts[11].id	https://openalex.org/C126322002
concepts[11].level	1
concepts[11].score	0.32482221722602844
concepts[11].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[11].display_name	Internal medicine
concepts[12].id	https://openalex.org/C197934379
concepts[12].level	2
concepts[12].score	0.2942298650741577
concepts[12].wikidata	https://www.wikidata.org/wiki/Q2047938
concepts[12].display_name	Adverse effect
concepts[13].id	https://openalex.org/C86803240
concepts[13].level	0
concepts[13].score	0.18893086910247803
concepts[13].wikidata	https://www.wikidata.org/wiki/Q420
concepts[13].display_name	Biology
concepts[14].id	https://openalex.org/C95444343
concepts[14].level	1
concepts[14].score	0.07422685623168945
concepts[14].wikidata	https://www.wikidata.org/wiki/Q7141
concepts[14].display_name	Cell biology
keywords[0].id	https://openalex.org/keywords/immune-system
keywords[0].score	0.6995174884796143
keywords[0].display_name	Immune system
keywords[1].id	https://openalex.org/keywords/tolerability
keywords[1].score	0.6951682567596436
keywords[1].display_name	Tolerability
keywords[2].id	https://openalex.org/keywords/pharmacodynamics
keywords[2].score	0.5622907876968384
keywords[2].display_name	Pharmacodynamics
keywords[3].id	https://openalex.org/keywords/medicine
keywords[3].score	0.5278306603431702
keywords[3].display_name	Medicine
keywords[4].id	https://openalex.org/keywords/antibody
keywords[4].score	0.5156580209732056
keywords[4].display_name	Antibody
keywords[5].id	https://openalex.org/keywords/extracellular-matrix
keywords[5].score	0.5141211152076721
keywords[5].display_name	Extracellular matrix
keywords[6].id	https://openalex.org/keywords/cancer-research
keywords[6].score	0.4947476089000702
keywords[6].display_name	Cancer research
keywords[7].id	https://openalex.org/keywords/tumor-microenvironment
keywords[7].score	0.4843903183937073
keywords[7].display_name	Tumor microenvironment
keywords[8].id	https://openalex.org/keywords/pharmacokinetics
keywords[8].score	0.4109783470630646
keywords[8].display_name	Pharmacokinetics
keywords[9].id	https://openalex.org/keywords/pharmacology
keywords[9].score	0.37706029415130615
keywords[9].display_name	Pharmacology
keywords[10].id	https://openalex.org/keywords/immunology
keywords[10].score	0.3280024528503418
keywords[10].display_name	Immunology
keywords[11].id	https://openalex.org/keywords/internal-medicine
keywords[11].score	0.32482221722602844
keywords[11].display_name	Internal medicine
keywords[12].id	https://openalex.org/keywords/adverse-effect
keywords[12].score	0.2942298650741577
keywords[12].display_name	Adverse effect
keywords[13].id	https://openalex.org/keywords/biology
keywords[13].score	0.18893086910247803
keywords[13].display_name	Biology
keywords[14].id	https://openalex.org/keywords/cell-biology
keywords[14].score	0.07422685623168945
keywords[14].display_name	Cell biology
language	en
locations[0].id	doi:10.1136/jitc-2021-sitc2021.487
locations[0].is_oa	True
locations[0].source.id	https://openalex.org/S4363604233
locations[0].source.issn
locations[0].source.type	journal
locations[0].source.is_oa	False
locations[0].source.issn_l
locations[0].source.is_core	True
locations[0].source.is_in_doaj	False
locations[0].source.display_name	Regular and Young Investigator Award Abstracts
locations[0].source.host_organization
locations[0].source.host_organization_name
locations[0].license
locations[0].pdf_url	https://jitc.bmj.com/content/jitc/9/Suppl_2/A516.full.pdf
locations[0].version	publishedVersion
locations[0].raw_type	proceedings-article
locations[0].license_id
locations[0].is_accepted	True
locations[0].is_published	True
locations[0].raw_source_name	Regular and Young Investigator Award Abstracts
locations[0].landing_page_url	https://doi.org/10.1136/jitc-2021-sitc2021.487
locations[1].id	pmh:oai:doaj.org/article:423b3164c15e49ecb0b9edf6ad3ceaf3
locations[1].is_oa	True
locations[1].source.id	https://openalex.org/S4306401280
locations[1].source.issn
locations[1].source.type	repository
locations[1].source.is_oa	False
locations[1].source.issn_l
locations[1].source.is_core	False
locations[1].source.is_in_doaj	False
locations[1].source.display_name	DOAJ (DOAJ: Directory of Open Access Journals)
locations[1].source.host_organization
locations[1].source.host_organization_name
locations[1].license	cc-by-sa
locations[1].pdf_url
locations[1].version	submittedVersion
locations[1].raw_type	article
locations[1].license_id	https://openalex.org/licenses/cc-by-sa
locations[1].is_accepted	False
locations[1].is_published	False
locations[1].raw_source_name	Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
locations[1].landing_page_url	https://doaj.org/article/423b3164c15e49ecb0b9edf6ad3ceaf3
indexed_in	crossref, doaj
authorships[0].author.id	https://openalex.org/A5049433895
authorships[0].author.orcid
authorships[0].author.display_name	Han Myint
authorships[0].affiliations[0].raw_affiliation_string	NextCure LLC, Beltsville, MD, USA
authorships[0].author_position	first
authorships[0].raw_author_name	Han Myint
authorships[0].is_corresponding	False
authorships[0].raw_affiliation_strings	NextCure LLC, Beltsville, MD, USA
authorships[1].author.id	https://openalex.org/A5110487860
authorships[1].author.orcid
authorships[1].author.display_name	Linjie Tian
authorships[1].affiliations[0].raw_affiliation_string	NextCure LLC, Beltsville, MD, USA
authorships[1].author_position	middle
authorships[1].raw_author_name	Linjie Tian
authorships[1].is_corresponding	False
authorships[1].raw_affiliation_strings	NextCure LLC, Beltsville, MD, USA
authorships[2].author.id	https://openalex.org/A5052958888
authorships[2].author.orcid	https://orcid.org/0000-0001-5509-6570
authorships[2].author.display_name	Jahangheer Shaik
authorships[2].affiliations[0].raw_affiliation_string	NextCure LLC, Beltsville, MD, USA
authorships[2].author_position	middle
authorships[2].raw_author_name	Jahangheer Shaik
authorships[2].is_corresponding	False
authorships[2].raw_affiliation_strings	NextCure LLC, Beltsville, MD, USA
authorships[3].author.id	https://openalex.org/A5028775704
authorships[3].author.orcid
authorships[3].author.display_name	Emilia Barbu
authorships[3].affiliations[0].raw_affiliation_string	NextCure LLC, Beltsville, MD, USA
authorships[3].author_position	middle
authorships[3].raw_author_name	Emilia Barbu
authorships[3].is_corresponding	False
authorships[3].raw_affiliation_strings	NextCure LLC, Beltsville, MD, USA
authorships[4].author.id	https://openalex.org/A5085102634
authorships[4].author.orcid	https://orcid.org/0000-0002-1321-7490
authorships[4].author.display_name	Qinjie Zhou
authorships[4].affiliations[0].raw_affiliation_string	NextCure LLC, Beltsville, MD, USA
authorships[4].author_position	middle
authorships[4].raw_author_name	Qinjie Zhou
authorships[4].is_corresponding	False
authorships[4].raw_affiliation_strings	NextCure LLC, Beltsville, MD, USA
authorships[5].author.id	https://openalex.org/A5088114256
authorships[5].author.orcid	https://orcid.org/0000-0001-5995-0527
authorships[5].author.display_name	Aaron Morawski
authorships[5].affiliations[0].raw_affiliation_string	NextCure LLC, Beltsville, MD, USA
authorships[5].author_position	middle
authorships[5].raw_author_name	Aaron Morawski
authorships[5].is_corresponding	False
authorships[5].raw_affiliation_strings	NextCure LLC, Beltsville, MD, USA
authorships[6].author.id	https://openalex.org/A5039347347
authorships[6].author.orcid	https://orcid.org/0009-0005-3088-573X
authorships[6].author.display_name	Hasan Abukharma
authorships[6].affiliations[0].raw_affiliation_string	NextCure LLC, Beltsville, MD, USA
authorships[6].author_position	middle
authorships[6].raw_author_name	Hasan Abukharma
authorships[6].is_corresponding	False
authorships[6].raw_affiliation_strings	NextCure LLC, Beltsville, MD, USA
authorships[7].author.id	https://openalex.org/A5031896207
authorships[7].author.orcid	https://orcid.org/0000-0003-3687-9291
authorships[7].author.display_name	Linda Liu
authorships[7].affiliations[0].raw_affiliation_string	NextCure LLC, Beltsville, MD, USA
authorships[7].author_position	middle
authorships[7].raw_author_name	Linda Liu
authorships[7].is_corresponding	False
authorships[7].raw_affiliation_strings	NextCure LLC, Beltsville, MD, USA
authorships[8].author.id	https://openalex.org/A5072188467
authorships[8].author.orcid	https://orcid.org/0000-0003-4490-0054
authorships[8].author.display_name	John Y. Shin
authorships[8].countries	US
authorships[8].affiliations[0].institution_ids	https://openalex.org/I4210140884
authorships[8].affiliations[0].raw_affiliation_string	National Cancer Institute, Bethesda, MD, USA
authorships[8].institutions[0].id	https://openalex.org/I4210140884
authorships[8].institutions[0].ror	https://ror.org/040gcmg81
authorships[8].institutions[0].type	government
authorships[8].institutions[0].lineage	https://openalex.org/I1299022934, https://openalex.org/I1299303238, https://openalex.org/I4210140884
authorships[8].institutions[0].country_code	US
authorships[8].institutions[0].display_name	National Cancer Institute
authorships[8].author_position	middle
authorships[8].raw_author_name	John Shin
authorships[8].is_corresponding	False
authorships[8].raw_affiliation_strings	National Cancer Institute, Bethesda, MD, USA
authorships[9].author.id	https://openalex.org/A5043413904
authorships[9].author.orcid	https://orcid.org/0000-0002-9280-2080
authorships[9].author.display_name	Dallas B. Flies
authorships[9].affiliations[0].raw_affiliation_string	NextCure LLC, Beltsville, MD, USA
authorships[9].author_position	middle
authorships[9].raw_author_name	Dallas Flies
authorships[9].is_corresponding	False
authorships[9].raw_affiliation_strings	NextCure LLC, Beltsville, MD, USA
authorships[10].author.id	https://openalex.org/A5084829527
authorships[10].author.orcid
authorships[10].author.display_name	Ron Copeland
authorships[10].affiliations[0].raw_affiliation_string	NextCure LLC, Beltsville, MD, USA
authorships[10].author_position	middle
authorships[10].raw_author_name	Ron Copeland
authorships[10].is_corresponding	False
authorships[10].raw_affiliation_strings	NextCure LLC, Beltsville, MD, USA
authorships[11].author.id	https://openalex.org/A5038965846
authorships[11].author.orcid
authorships[11].author.display_name	Megan Nelson
authorships[11].affiliations[0].raw_affiliation_string	NextCure LLC, Beltsville, MD, USA
authorships[11].author_position	middle
authorships[11].raw_author_name	Megan Nelson
authorships[11].is_corresponding	False
authorships[11].raw_affiliation_strings	NextCure LLC, Beltsville, MD, USA
authorships[12].author.id	https://openalex.org/A5016052224
authorships[12].author.orcid
authorships[12].author.display_name	Stephanie Zeidan
authorships[12].affiliations[0].raw_affiliation_string	NextCure LLC, Beltsville, MD, USA
authorships[12].author_position	middle
authorships[12].raw_author_name	Stephanie Zeidan
authorships[12].is_corresponding	False
authorships[12].raw_affiliation_strings	NextCure LLC, Beltsville, MD, USA
authorships[13].author.id	https://openalex.org/A5046542135
authorships[13].author.orcid	https://orcid.org/0000-0003-1020-689X
authorships[13].author.display_name	Marijo Bilušić
authorships[13].countries	US
authorships[13].affiliations[0].institution_ids	https://openalex.org/I4210140884
authorships[13].affiliations[0].raw_affiliation_string	National Cancer Institute, Bethesda, MD, USA
authorships[13].institutions[0].id	https://openalex.org/I4210140884
authorships[13].institutions[0].ror	https://ror.org/040gcmg81
authorships[13].institutions[0].type	government
authorships[13].institutions[0].lineage	https://openalex.org/I1299022934, https://openalex.org/I1299303238, https://openalex.org/I4210140884
authorships[13].institutions[0].country_code	US
authorships[13].institutions[0].display_name	National Cancer Institute
authorships[13].author_position	middle
authorships[13].raw_author_name	Marijo Bilusic
authorships[13].is_corresponding	False
authorships[13].raw_affiliation_strings	National Cancer Institute, Bethesda, MD, USA
authorships[14].author.id	https://openalex.org/A5110610575
authorships[14].author.orcid
authorships[14].author.display_name	Danielle M. Pastor
authorships[14].countries	US
authorships[14].affiliations[0].institution_ids	https://openalex.org/I4210140884
authorships[14].affiliations[0].raw_affiliation_string	National Cancer Institute, Bethesda, MD, USA
authorships[14].institutions[0].id	https://openalex.org/I4210140884
authorships[14].institutions[0].ror	https://ror.org/040gcmg81
authorships[14].institutions[0].type	government
authorships[14].institutions[0].lineage	https://openalex.org/I1299022934, https://openalex.org/I1299303238, https://openalex.org/I4210140884
authorships[14].institutions[0].country_code	US
authorships[14].institutions[0].display_name	National Cancer Institute
authorships[14].author_position	middle
authorships[14].raw_author_name	Danielle Pastor
authorships[14].is_corresponding	False
authorships[14].raw_affiliation_strings	National Cancer Institute, Bethesda, MD, USA
authorships[15].author.id	https://openalex.org/A5044285326
authorships[15].author.orcid	https://orcid.org/0000-0001-5106-8636
authorships[15].author.display_name	Ravi A. Madan
authorships[15].countries	US
authorships[15].affiliations[0].institution_ids	https://openalex.org/I4210140884
authorships[15].affiliations[0].raw_affiliation_string	National Cancer Institute, Bethesda, MD, USA
authorships[15].institutions[0].id	https://openalex.org/I4210140884
authorships[15].institutions[0].ror	https://ror.org/040gcmg81
authorships[15].institutions[0].type	government
authorships[15].institutions[0].lineage	https://openalex.org/I1299022934, https://openalex.org/I1299303238, https://openalex.org/I4210140884
authorships[15].institutions[0].country_code	US
authorships[15].institutions[0].display_name	National Cancer Institute
authorships[15].author_position	middle
authorships[15].raw_author_name	Ravi Madan
authorships[15].is_corresponding	False
authorships[15].raw_affiliation_strings	National Cancer Institute, Bethesda, MD, USA
authorships[16].author.id	https://openalex.org/A5045197829
authorships[16].author.orcid	https://orcid.org/0000-0002-1933-0419
authorships[16].author.display_name	Siqing Fu
authorships[16].countries	US
authorships[16].affiliations[0].institution_ids	https://openalex.org/I1343551460
authorships[16].affiliations[0].raw_affiliation_string	MD Anderson Cancer Center, Houston, TX, USA
authorships[16].institutions[0].id	https://openalex.org/I1343551460
authorships[16].institutions[0].ror	https://ror.org/04twxam07
authorships[16].institutions[0].type	healthcare
authorships[16].institutions[0].lineage	https://openalex.org/I1343551460
authorships[16].institutions[0].country_code	US
authorships[16].institutions[0].display_name	The University of Texas MD Anderson Cancer Center
authorships[16].author_position	middle
authorships[16].raw_author_name	Siqing Fu
authorships[16].is_corresponding	False
authorships[16].raw_affiliation_strings	MD Anderson Cancer Center, Houston, TX, USA
authorships[17].author.id	https://openalex.org/A5022339242
authorships[17].author.orcid	https://orcid.org/0000-0003-3156-3159
authorships[17].author.display_name	Martin Gutierrez
authorships[17].countries	US
authorships[17].affiliations[0].institution_ids	https://openalex.org/I1324520350
authorships[17].affiliations[0].raw_affiliation_string	Hackensack Cancer Center, Hackensack, NJ, USA
authorships[17].institutions[0].id	https://openalex.org/I1324520350
authorships[17].institutions[0].ror	https://ror.org/008zj0x80
authorships[17].institutions[0].type	healthcare
authorships[17].institutions[0].lineage	https://openalex.org/I1324520350
authorships[17].institutions[0].country_code	US
authorships[17].institutions[0].display_name	Hackensack University Medical Center
authorships[17].author_position	middle
authorships[17].raw_author_name	Martin Gutierrez
authorships[17].is_corresponding	False
authorships[17].raw_affiliation_strings	Hackensack Cancer Center, Hackensack, NJ, USA
authorships[18].author.id	https://openalex.org/A5019781852
authorships[18].author.orcid	https://orcid.org/0000-0002-9596-4931
authorships[18].author.display_name	Solomon Langermann
authorships[18].affiliations[0].raw_affiliation_string	NextCure LLC, Beltsville, MD, USA
authorships[18].author_position	last
authorships[18].raw_author_name	Solomon Langermann
authorships[18].is_corresponding	False
authorships[18].raw_affiliation_strings	NextCure LLC, Beltsville, MD, USA
has_content.pdf	True
has_content.grobid_xml	True
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://jitc.bmj.com/content/jitc/9/Suppl_2/A516.full.pdf
open_access.oa_status	bronze
open_access.any_repository_has_fulltext	False
created_date	2021-11-22T00:00:00
display_name	487 NC410, a fusion protein of LAIR-2 (Leukocyte Associated Immunoglobulin-like Receptor) with human IgG1 Fc, is safe & tolerable with evidence of immune modulation in subjects with advanced solid tumors
has_fulltext	True
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T10158
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.9930999875068665
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2730
primary_topic.subfield.display_name	Oncology
primary_topic.display_name	Cancer Immunotherapy and Biomarkers
related_works	https://openalex.org/W4311628015, https://openalex.org/W3191427281, https://openalex.org/W2087016115, https://openalex.org/W2305775430, https://openalex.org/W2783315223, https://openalex.org/W1490050402, https://openalex.org/W1990197915, https://openalex.org/W2465571689, https://openalex.org/W2254638634, https://openalex.org/W2369345461
cited_by_count	1
counts_by_year[0].year	2022
counts_by_year[0].cited_by_count	1
locations_count	2
best_oa_location.id	doi:10.1136/jitc-2021-sitc2021.487
best_oa_location.is_oa	True
best_oa_location.source.id	https://openalex.org/S4363604233
best_oa_location.source.issn
best_oa_location.source.type	journal
best_oa_location.source.is_oa	False
best_oa_location.source.issn_l
best_oa_location.source.is_core	True
best_oa_location.source.is_in_doaj	False
best_oa_location.source.display_name	Regular and Young Investigator Award Abstracts
best_oa_location.source.host_organization
best_oa_location.source.host_organization_name
best_oa_location.license
best_oa_location.pdf_url	https://jitc.bmj.com/content/jitc/9/Suppl_2/A516.full.pdf
best_oa_location.version	publishedVersion
best_oa_location.raw_type	proceedings-article
best_oa_location.license_id
best_oa_location.is_accepted	True
best_oa_location.is_published	True
best_oa_location.raw_source_name	Regular and Young Investigator Award Abstracts
best_oa_location.landing_page_url	https://doi.org/10.1136/jitc-2021-sitc2021.487
primary_location.id	doi:10.1136/jitc-2021-sitc2021.487
primary_location.is_oa	True
primary_location.source.id	https://openalex.org/S4363604233
primary_location.source.issn
primary_location.source.type	journal
primary_location.source.is_oa	False
primary_location.source.issn_l
primary_location.source.is_core	True
primary_location.source.is_in_doaj	False
primary_location.source.display_name	Regular and Young Investigator Award Abstracts
primary_location.source.host_organization
primary_location.source.host_organization_name
primary_location.license
primary_location.pdf_url	https://jitc.bmj.com/content/jitc/9/Suppl_2/A516.full.pdf
primary_location.version	publishedVersion
primary_location.raw_type	proceedings-article
primary_location.license_id
primary_location.is_accepted	True
primary_location.is_published	True
primary_location.raw_source_name	Regular and Young Investigator Award Abstracts
primary_location.landing_page_url	https://doi.org/10.1136/jitc-2021-sitc2021.487
publication_date	2021-11-01
publication_year	2021
referenced_works_count	0
abstract_inverted_index.2	139
abstract_inverted_index.5	243
abstract_inverted_index.A	451
abstract_inverted_index.T	311, 315
abstract_inverted_index.a	35, 50, 77, 115, 174, 266, 288, 302, 384
abstract_inverted_index.16	177
abstract_inverted_index.4,	319
abstract_inverted_index.60	191, 214
abstract_inverted_index.As	171, 217
abstract_inverted_index.No	205
abstract_inverted_index.an	15, 280, 305
abstract_inverted_index.as	49, 343, 347
abstract_inverted_index.be	341, 369, 392
abstract_inverted_index.by	93, 412, 461
abstract_inverted_index.in	4, 80, 117, 250, 265, 282, 287, 307, 317, 359, 383, 430
abstract_inverted_index.is	114, 457
abstract_inverted_index.mg	215
abstract_inverted_index.no	197, 248
abstract_inverted_index.of	23, 38, 61, 67, 148, 172, 176, 297, 324, 357, 375, 415, 444, 453, 464
abstract_inverted_index.on	19, 167
abstract_inverted_index.or	159, 202, 363
abstract_inverted_index.to	43, 53, 87, 104, 125, 144, 190, 213, 237, 241, 263, 291, 329, 368, 397
abstract_inverted_index.up	212, 240
abstract_inverted_index.we	278, 348
abstract_inverted_index.(up	189
abstract_inverted_index.1).	151
abstract_inverted_index.1/2	386
abstract_inverted_index.2).	259
abstract_inverted_index.3).	276
abstract_inverted_index.4).	294
abstract_inverted_index.C1Q	220, 253
abstract_inverted_index.C1q	3, 46, 70
abstract_inverted_index.DLT	186, 203
abstract_inverted_index.ECM	63, 102
abstract_inverted_index.IRB	414
abstract_inverted_index.Key	152
abstract_inverted_index.all	416, 421
abstract_inverted_index.and	2, 32, 45, 47, 64, 69, 100, 143, 183, 228, 271, 309, 335, 371, 420, 447
abstract_inverted_index.any	448
abstract_inverted_index.are	9
abstract_inverted_index.did	326
abstract_inverted_index.for	13, 41, 442, 459
abstract_inverted_index.has	409
abstract_inverted_index.not	327
abstract_inverted_index.the	5, 10, 20, 62, 72, 110, 127, 185, 219, 225, 251, 413, 417, 431, 440, 454, 462
abstract_inverted_index.two	232
abstract_inverted_index.was	85, 193, 209, 229, 247, 437
abstract_inverted_index.1/2,	120
abstract_inverted_index.CD4+	308
abstract_inverted_index.CD8+	310
abstract_inverted_index.TME.	111
abstract_inverted_index.This	113, 407
abstract_inverted_index.been	180, 410
abstract_inverted_index.cell	21, 26, 107
abstract_inverted_index.copy	452
abstract_inverted_index.date	238
abstract_inverted_index.done	393
abstract_inverted_index.dose	135, 352
abstract_inverted_index.from	235, 439
abstract_inverted_index.have	179, 423
abstract_inverted_index.mg),	192
abstract_inverted_index.over	285
abstract_inverted_index.part	429
abstract_inverted_index.role	79
abstract_inverted_index.safe	370
abstract_inverted_index.that	28, 245
abstract_inverted_index.this	89, 445, 465
abstract_inverted_index.time	286
abstract_inverted_index.well	194
abstract_inverted_index.will	340, 391
abstract_inverted_index.with	157, 163, 196, 255, 361, 373, 379, 394
abstract_inverted_index.(ADA)	208
abstract_inverted_index.(CDP)	339
abstract_inverted_index.(TME)	75
abstract_inverted_index.NC410	84, 149, 188, 226, 358
abstract_inverted_index.PK/PD	381
abstract_inverted_index.Phase	385
abstract_inverted_index.after	224, 231
abstract_inverted_index.based	166
abstract_inverted_index.blood	300
abstract_inverted_index.cells	312, 316
abstract_inverted_index.cycle	242
abstract_inverted_index.decoy	52
abstract_inverted_index.dose,	140
abstract_inverted_index.doses	396
abstract_inverted_index.first	116
abstract_inverted_index.given	424
abstract_inverted_index.level	221, 254
abstract_inverted_index.phase	119, 138
abstract_inverted_index.plays	76
abstract_inverted_index.solid	161, 365
abstract_inverted_index.study	124, 408
abstract_inverted_index.there	246
abstract_inverted_index.these	399
abstract_inverted_index.total	175
abstract_inverted_index.trend	303
abstract_inverted_index.tumor	73, 82
abstract_inverted_index.under	57
abstract_inverted_index.v1.1.	169
abstract_inverted_index.whole	299
abstract_inverted_index.(DLT),	132
abstract_inverted_index.(ECM),	8
abstract_inverted_index.(MTD),	136
abstract_inverted_index.Editor	463
abstract_inverted_index.LAIR-1	95, 284, 325
abstract_inverted_index.LAIR-2	260, 292
abstract_inverted_index.RECIST	168
abstract_inverted_index.appear	328
abstract_inverted_index.before	427
abstract_inverted_index.cohort	318
abstract_inverted_index.dosing	257, 270
abstract_inverted_index.higher	351
abstract_inverted_index.highly	90
abstract_inverted_index.hours.	233
abstract_inverted_index.human,	118
abstract_inverted_index.immune	25, 30, 55, 98, 106, 376
abstract_inverted_index.levels	261, 323
abstract_inverted_index.matrix	7
abstract_inverted_index.normal	58
abstract_inverted_index.review	460
abstract_inverted_index.safety	198
abstract_inverted_index.serves	48
abstract_inverted_index.study.	388, 432
abstract_inverted_index.taking	428
abstract_inverted_index.tumors	162, 366
abstract_inverted_index.within	71, 109
abstract_inverted_index.(figure	150, 258, 275, 293
abstract_inverted_index.Further	389
abstract_inverted_index.LAIR-1+	314
abstract_inverted_index.LAIR-1,	14, 39
abstract_inverted_index.LAIR-2,	34
abstract_inverted_index.Written	434
abstract_inverted_index.appears	367
abstract_inverted_index.binding	42
abstract_inverted_index.confirm	398
abstract_inverted_index.consent	426, 436, 456
abstract_inverted_index.disease	165
abstract_inverted_index.explore	145
abstract_inverted_index.fashion	268
abstract_inverted_index.homolog	37
abstract_inverted_index.images.	450
abstract_inverted_index.include	155
abstract_inverted_index.initial	400
abstract_inverted_index.ligands	12
abstract_inverted_index.maximum	133
abstract_inverted_index.natural	51
abstract_inverted_index.overall	321
abstract_inverted_index.patient	298, 441
abstract_inverted_index.pattern	290
abstract_inverted_index.period.	187
abstract_inverted_index.promote	54, 105
abstract_inverted_index.safety,	128
abstract_inverted_index.samples	236
abstract_inverted_index.several	24
abstract_inverted_index.similar	289
abstract_inverted_index.soluble	36, 283
abstract_inverted_index.subsets	27
abstract_inverted_index.surface	22
abstract_inverted_index.through	350
abstract_inverted_index.towards	304
abstract_inverted_index.written	455
abstract_inverted_index.(ongoing	331
abstract_inverted_index.Collagen	1
abstract_inverted_index.abstract	446
abstract_inverted_index.advanced	158, 362
abstract_inverted_index.although	320
abstract_inverted_index.antibody	207
abstract_inverted_index.approved	411
abstract_inverted_index.baseline	252
abstract_inverted_index.blocking	94
abstract_inverted_index.cohorts.	353
abstract_inverted_index.collagen	44, 68, 336
abstract_inverted_index.competes	40
abstract_inverted_index.continue	349
abstract_inverted_index.criteria	154
abstract_inverted_index.critical	78
abstract_inverted_index.detected	210
abstract_inverted_index.efficacy	142
abstract_inverted_index.evidence	374
abstract_inverted_index.function	56
abstract_inverted_index.increase	264, 273, 281, 306, 330
abstract_inverted_index.inducing	101
abstract_inverted_index.informed	425, 435
abstract_inverted_index.infusion	227
abstract_inverted_index.inhibits	29
abstract_inverted_index.journal.	466
abstract_inverted_index.marginal	272
abstract_inverted_index.modeling	382
abstract_inverted_index.observed	279
abstract_inverted_index.obtained	438
abstract_inverted_index.overcome	88
abstract_inverted_index.patients	178
abstract_inverted_index.pre-dose	274
abstract_inverted_index.products	338
abstract_inverted_index.receptor	17
abstract_inverted_index.subjects	156, 360
abstract_inverted_index.suggests	244, 301
abstract_inverted_index.toxicity	131
abstract_inverted_index.treated,	182
abstract_inverted_index.<h3>Trial	402
abstract_inverted_index.anti-drug	206
abstract_inverted_index.available	239, 458
abstract_inverted_index.completed	184
abstract_inverted_index.concerns,	199
abstract_inverted_index.continued	262
abstract_inverted_index.decreased	222
abstract_inverted_index.determine	126
abstract_inverted_index.enrolled,	181
abstract_inverted_index.evaluated	342
abstract_inverted_index.expected,	218
abstract_inverted_index.expressed	18
abstract_inverted_index.findings.	401
abstract_inverted_index.function,	96
abstract_inverted_index.including	313
abstract_inverted_index.increased	65
abstract_inverted_index.potential	344
abstract_inverted_index.promoting	81
abstract_inverted_index.reduction	249
abstract_inverted_index.reported.	204
abstract_inverted_index.reversing	97
abstract_inverted_index.tolerated	134
abstract_inverted_index.<h3>Ethics	405
abstract_inverted_index.Cytokines,	333
abstract_inverted_index.Evaluation	234
abstract_inverted_index.activation	31
abstract_inverted_index.analysis).	332
abstract_inverted_index.biomarkers	147, 346
abstract_inverted_index.consistent	378
abstract_inverted_index.engineered	86
abstract_inverted_index.evaluation	356, 390
abstract_inverted_index.expression	66, 322
abstract_inverted_index.increasing	395
abstract_inverted_index.inhibitory	16
abstract_inverted_index.measurable	164
abstract_inverted_index.metastatic	160, 364
abstract_inverted_index.migration.	33
abstract_inverted_index.modulation	377
abstract_inverted_index.open-label	387
abstract_inverted_index.post-NC410	211, 269
abstract_inverted_index.predictive	380
abstract_inverted_index.remodeling	103
abstract_inverted_index.subsequent	256
abstract_inverted_index.tolerated,	195
abstract_inverted_index.treatment.	216
abstract_inverted_index.07/22/2021,	173
abstract_inverted_index.NCT04408599	404
abstract_inverted_index.Preliminary	355
abstract_inverted_index.chemokines,	334
abstract_inverted_index.conditions.	59
abstract_inverted_index.degradation	337
abstract_inverted_index.eligibility	153
abstract_inverted_index.environment	92
abstract_inverted_index.immediately	223
abstract_inverted_index.open-label,	121
abstract_inverted_index.predominant	11
abstract_inverted_index.preliminary	141
abstract_inverted_index.publication	443
abstract_inverted_index.recommended	137
abstract_inverted_index.replenished	230
abstract_inverted_index.toxicities,	201
abstract_inverted_index.Furthermore,	295
abstract_inverted_index.accompanying	449
abstract_inverted_index.infiltration	108
abstract_inverted_index.participants	422
abstract_inverted_index.progression.	83
abstract_inverted_index.single-armed	122
abstract_inverted_index.suppression,	99
abstract_inverted_index.Approval</h3>	406
abstract_inverted_index.Dysregulation	60
abstract_inverted_index.dose-limiting	130
abstract_inverted_index.extracellular	6
abstract_inverted_index.institutions,	419
abstract_inverted_index.participating	418
abstract_inverted_index.tolerability,	129
abstract_inverted_index.Interestingly,	277
abstract_inverted_index.dose-dependent	267
abstract_inverted_index.well-tolerated	372
abstract_inverted_index.dose-escalation	123
abstract_inverted_index.pharmacodynamic	146, 345
abstract_inverted_index.<h3>Consent</h3>	433
abstract_inverted_index.<h3>Methods</h3>	112
abstract_inverted_index.<h3>Results</h3>	170
abstract_inverted_index.infusion-related	200
abstract_inverted_index.microenvironment	74
abstract_inverted_index.Registration</h3>	403
abstract_inverted_index.immunophenotyping	296
abstract_inverted_index.immunosuppressive	91
abstract_inverted_index.<h3>Background</h3>	0
abstract_inverted_index.<h3>Conclusions</h3>	354
cited_by_percentile_year.max	94
cited_by_percentile_year.min	89
countries_distinct_count	1
institutions_distinct_count	19
sustainable_development_goals[0].id	https://metadata.un.org/sdg/3
sustainable_development_goals[0].score	0.7900000214576721
sustainable_development_goals[0].display_name	Good health and well-being
citation_normalized_percentile.value	0.49389538
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False